 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ABN501 / Abion
?-ABN501, a novel antibody targeting claudin-3, demonstrates the potential to be a new therapeutic option for small cell lung cancer (Section 22) - Mar 5, 2024 - Abstract #AACR2024AACR_3925;
Present study data sets suggest that the ?-ABN501 can be a potential new therapeutic option for SCLC. In addition, the ?-ABN501 antibody is currently under way of development into new drug platforms for further applications.
- ABN501 / Abion
ABN501, a novel anti-claudin-3 antibody, shows potent anti-cancer activity in vitro and in vivo (Section 13; Poster Board #21) - Mar 14, 2023 - Abstract #AACR2023AACR_4877;
In summary, we suggest that ABN501 can be used as promising tissue-agnostic drug candidates as therapeutics for various types of claudin-3-positive cancers. ABN501 is currently developed with various antibody engineering platforms.